Pneumagen
Douglas Thomson has significant international experience as CEO, Chairman, NXD and Business Development Director. He has led executive teams generating rapid value creation at companies such as 4D Pharma. Working with Thomas Engelen to deliver the Company’s strategic objectives, Douglas accesses an extensive network of industry experts and service providers to drive forward Pneumagen’s products and technologies. He has executed multiple commercial deals with biotechnology and pharmaceutical companies.
This person is not in any teams
This person is not in any offices
Pneumagen
1 followers
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.